Charles River Laboratories Q3 2025 earnings: revenue steady, profitability improves
The contract research firm held revenue roughly flat, widened its operating margin, and raised its full-year profit outlook while continuing cost cuts.
| Q3 2025 | Reported |
|---|---|
| EPS | $1.10 |
| Revenue | $1.00B |
Figures as reported by the company to the SEC for the quarter ended September 27, 2025. Analyst estimates are not part of a filing, so no comparison to expectations is shown.
Key takeaways
- Total revenue was essentially flat versus a year earlier at about $1.00 billion. Stripping out currency effects and a small facility sale from 2024, revenue on an “organic” basis (comparing like-for-like operations) actually declined 1.6%, showing the core business still contracted slightly even as the headline number looked steady.
- Results varied a lot by division: the Research Models and Services segment, which breeds and sells lab animals and related services, grew revenue about 8%. That growth was offset by declines in the Discovery and Safety Assessment segment (drug-safety testing) and the Manufacturing Solutions segment.
- The company’s operating margin (the share of revenue left after core operating costs) rose to 13.3% from 11.6% a year earlier, mainly because it spent less this quarter on restructuring charges than in the same period last year.
- Charles River narrowed its full-year 2025 revenue guidance toward the higher end of its prior range and reaffirmed its non-GAAP profit outlook, saying the update mainly reflects that third-quarter performance came in modestly ahead of its own earlier internal expectations.
- Management pointed to signs of stabilizing client demand: proposal activity from both large pharmaceutical and biotech customers increased, contract cancellations declined, and the ratio of new bookings to billings improved over the prior several months, though it remained below the level needed to signal a full recovery.
- The company said it is expanding cost-cutting efforts, targeting $295 million in annual savings by 2026 from restructuring, procurement changes, and consolidating administrative functions – part of a broader push to protect profitability while revenue growth stays muted.
- The board approved a new $1 billion stock buyback program and said it is moving ahead with plans to divest business units representing about 7% of this year’s expected revenue, changes it expects to add to per-share earnings once completed.
- Looking at the trailing twelve months, the company’s overall net profit margin was negative, but that reflects a large one-time non-cash impairment charge (a write-down of acquired business value) taken in the fourth quarter of 2024 – not a sign that the current quarter’s underlying operations were unprofitable, since Charles River reported a GAAP operating profit in Q3 2025.
Q3 2025 in context
| Metric | Sep 2025 | Sep 2024 | Change |
|---|---|---|---|
| Revenue | $1.0B | $1.0B | -0.5% |
| Net income | $54M | $70M | -21.9% |
| Free cash flow | $178M | $213M | -16.3% |
| Diluted EPS | $1.10 | $1.33 | -17.3% |
| Operating margin | 13.3% | 11.6% | +1.7 pts |
| Net margin | 5.4% | 6.9% | -1.5 pts |
Figures for the quarter ended Sep 2025 and the quarter ended Sep 2024, as reported to the SEC.
How the stock took it
Charles River Laboratories International Inc closed at $177.85 on Nov 4, 2025, the last session before the report, and at $170.88 on Nov 6, 2025, the first session after it — -3.9% across the report.
Closes from the market's daily record. Each figure spans the report date — from the last session that closed before it to the first that closed after — because a company may report before the open or after the close.
Sources: company report · earnings call